Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression

ConclusionTo acquire better benefits for HR-proficient breast cancer patients, developing chemotherapeutic drugs antagonize APE1 would be an effective strategy to improve the clinical outcome of PARP inhibitors.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research